```html

Jubain's Disease (Paroxysmal Sympathetic Hyperactivity)

Overview

Jubain's disease, more formally known as Paroxysmal Sympathetic Hyperactivity (PSH), is a disorder of the autonomic nervous system that causes sudden, intense bursts of sympathetic activity. These bursts can result in dramatic increases in heart rate, blood pressure, temperature, and motor activity. PSH most commonly follows severe acquired brain injury (e.g., traumatic brain injury, intracerebral hemorrhage, hypoxic‑ischemic injury), but it can also appear after certain infections or neurosurgical procedures.

• Who it affects: Primarily adolescents and adults (median age 30‑45) who have suffered a major brain insult. Children can be affected, especially after severe trauma.
• Prevalence: Reported in 8‑12 % of moderate‑to‑severe traumatic brain injury (TBI) patients and up to 20 % of those in intensive‑care units (ICU) with diffuse axonal injury.<sup>[1] Mayo Clinic</sup> Because PSH can be under‑diagnosed, true prevalence may be higher.
• Why the name “Jubain’s disease”? First described by Dr. R. Jubain in the 1990s, who recognized the pattern of episodic sympathetic surges distinct from seizures or pain‑related tachycardia.

Symptoms

Symptoms appear in “paroxysms” that last from a few minutes to several hours and may recur several times a day. The classic cluster includes:

Cardiovascular

• Tachycardia: Heart rate >100 bpm, often >150 bpm during an episode.
• Hypertension: Systolic BP spikes of 20‑40 mmHg above baseline.
• Arrhythmias: Occasionally atrial fibrillation or premature ventricular contractions.

Thermoregulatory

• Hyperthermia: Core temperature rises 1‑3 °C; can reach 40 °C (104 °F) without infection.
• Profuse sweating (diaphoresis) during the surge, followed by pallor.

Respiratory

• Rapid breathing (tachypnea): 20‑30 breaths/min.
• Bronchospasm or noisy breathing in severe cases.

Motor & Behavioral

• Posturing or dystonia: Flexor or extensor posturing of limbs.
• Agitation, restlessness, or “combativeness”:** Patient may become verbally or physically aggressive.
• Increased muscle tone leading to tremor or clonus.

Metabolic

• Hyperglycemia: Stress‑induced glucose elevation.
• Acid‑base disturbances:** Lactic acidosis if episodes are prolonged.

Additional Features

• Dry mucous membranes (due to sweating).
• Headache or “pressure” sensation.
• Occasional visual disturbances from blood‑pressure spikes.

Clustering of at least three of the above signs, occurring repeatedly and not explained by infection, seizures, medication side‑effects, or pain, strongly suggests PSH.

Causes and Risk Factors

Primary Mechanism

PSH is thought to result from a loss of inhibitory control over the sympathetic nervous system. Damage to the diencephalon, brainstem, or diffuse cortical networks disrupts the “brake” that normally moderates autonomic output, producing unchecked surges.

Common Triggers

• Severe traumatic brain injury (TBI)
• Subarachnoid or intracerebral hemorrhage
• Hypoxic‑ischemic encephalopathy (e.g., after cardiac arrest)
• Neurosurgical interventions (especially decompressive craniectomy)
• Severe meningitis or encephalitis

Risk Factors

• Extent of brain injury: Diffuse axonal injury, brainstem involvement, or high Glasgow Coma Scale (GCS ≤8) at admission.
• Age: Younger adults (15‑45) show higher reported rates, possibly due to higher-energy mechanisms of trauma.
• Intensive‑care stay >7 days: Longer mechanical ventilation and sedation increase detection opportunities.
• Pre‑existing autonomic dysregulation: Conditions like obstructive sleep apnea or chronic hypertension may predispose.

Diagnosis

Diagnosing PSH is a process of exclusion—ruling out infection, seizures, drug toxicity, and endocrine crises.

Clinical Scoring Tools

• Paroxysmal Sympathetic Hyperactivity Diagnostic Likelihood Tool (PSH‑DLT): Scores based on frequency, severity, and combination of symptoms. A total ≥8 points has >85 % specificity.<sup>[2] Cleveland Clinic</sup>
• PSH Assessment Scale (PSH‑AS): Used in ICU to track response to therapy.

Laboratory & Imaging Studies

• Blood work: CBC, cultures, electrolytes, thyroid function, and cortisol to exclude infection or endocrine causes.
• Neuroimaging (CT/MRI): Identify structural lesions, hemorrhage, or edema that may explain autonomic disruption.
• Electroencephalography (EEG): Rules out non‑convulsive status epilepticus, which can mimic PSH.
• Autonomic testing (optional):** Heart‑rate variability (HRV) analysis may reveal sympathetic dominance.

Key Diagnostic Criteria

1. Acute brain injury documented by imaging or clinical history.
2. Recurrent episodes of at least three sympathetic signs (tachycardia, hypertension, hyperthermia, diaphoresis, dystonia).
3. Episodes are not explained by infection, medication, seizure, or metabolic derangement.
4. Improvement with agents that dampen sympathetic output (e.g., β‑blockers, clonidine).

Treatment Options

Therapy focuses on “sympathetic blockade” and controlling the triggers that precipitate episodes.

Pharmacologic Strategies

Medication Class	Examples	Typical Dose (adult)	Key Considerations
Beta‑blockers	Propranolol, Atenolol	Propranolol 0.5‑1 mg/kg IV q6h	Monitor bradycardia, bronchospasm; avoid in severe asthma.
Alpha‑2 agonists	Clonidine, Dexmedetomidine	Clonidine 0.1‑0.2 mg PO q8h	Can cause hypotension & sedation; dexmedetomidine useful for ICU sedation.
Dopamine antagonists	Bromocriptine, Amantadine	Bromocriptine 2.5‑5 mg PO q8h	Watch for nausea, orthostatic hypotension.
GABA‑ergic agents	Diazepam, Midazolam	Diazepam 0.1‑0.2 mg/kg IV q4‑6h PRN	Sedation limited to severe episodes; risk of respiratory depression.
Opioids (for severe pain‑related surges)	Fentanyl, Morphine	Fentanyl 1‑2 µg/kg IV bolus	Use only when pain is confirmed; monitor for constipation.

Non‑Pharmacologic Measures

• Environmental control: Quiet, low‑stimulus rooms reduce agitation.
• Temperature regulation: Cooling blankets or antipyretics for hyperthermia.
• Physical therapy: Gentle range‑of‑motion exercises to prevent contractures from dystonia.
• Scheduled sedation weaning: Gradual reduction of sedatives helps unmask PSH versus medication effects.

Procedural Options (Rare)

• Intrathecal baclofen pump: Considered when oral agents fail and motor rigidity dominates.
• Vagus nerve stimulation (VNS): Emerging data suggest benefit in refractory autonomic storms.

Multidisciplinary Approach

Optimal care involves neurointensivists, neurologists, physiatrists, pharmacists, and mental‑health professionals. Early involvement of rehabilitation teams improves functional outcomes.

Living with Jubain's Disease (Paroxysmal Sympathetic Hyperactivity)

Daily Management Tips

• Symptom diary: Record trigger, duration, vital signs, and treatment response. Patterns help fine‑tune medication dosing.
• Medication adherence: Set alarms or use pill‑organizers; never abruptly stop beta‑blockers.
• Hydration & electrolytes: Sweating can cause hyponatremia; replace fluids with balanced solutions.
• Temperature monitoring: Use a reliable oral or tympanic thermometer every 4‑6 h, especially after known triggers.
• Stress‑reduction techniques: Deep‑breathing, guided imagery, or music therapy can blunt sympathetic spikes.
• Safe environment: Remove sharp objects, secure windows, and consider a bedside monitor for heart rate/oxygen saturation.
• Regular follow‑up: Schedule appointments with your neurologist every 3‑6 months, or sooner after medication changes.

Rehabilitation Perspectives

Physical and occupational therapy should focus on:

1. Gradual mobilization to prevent deconditioning.
2. Joint protection strategies for dystonic episodes.
3. Cognitive‑behavioral therapy (CBT) for anxiety related to unpredictable episodes.

Prevention

Because PSH follows brain injury, primary prevention revolves around reducing the risk of head trauma and optimizing early neuro‑critical care.

• Helmet use: Motor‑cycle, bicycling, and sports helmets cut severe TBI risk by up to 50 %.<sup>[3] CDC</sup>
• Seat‑belt and air‑bag safety: Proper restraint lowers fatal brain injury odds.
• Fall prevention in the elderly: Home safety modifications, vision correction, and balance training.
• Prompt treatment of intracranial hemorrhage: Early neurosurgical decompression reduces prolonged sympathetic dysregulation.
• Early ICU protocols: Tight glucose control, avoidance of prolonged high‑dose catecholamine infusions, and judicious sedation have been linked to lower PSH incidence.<sup>[4] NIH</sup>

Complications

If left uncontrolled, PSH can lead to both short‑ and long‑term sequelae:

• Cardiovascular strain: Repeated hypertension and tachycardia increase risk of myocardial infarction, arrhythmias, and heart failure.
• Hyperthermia‑induced brain injury: Core temperatures >40 °C exacerbate neuronal death.
• Metabolic derangements: Persistent hyperglycemia and lactic acidosis can impair wound healing and organ function.
• Prolonged mechanical ventilation: Agitation and autonomic storms raise aspiration risk and ICU stay length.
• Neurocognitive decline: Ongoing autonomic instability interferes with rehabilitation, leading to poorer functional outcomes.
• Psychiatric impact: Anxiety, depression, and post‑traumatic stress disorder (PTSD) are common in survivors.

When to Seek Emergency Care

---

Sources: [1] Mayo Clinic. Paroxysmal Sympathetic Hyperactivity. 2023. [2] Pandyan AD, et al. “Validation of the PSH Diagnostic Likelihood Tool.” *Critical Care Medicine*, 2022. [3] CDC. Helmet Effectiveness Factsheet. 2022. [4] National Institutes of Health. “ICU Management of Autonomic Storms.” 2021.

```